Niacor

Pellagra, Hardening of the Arteries, dietary supplementation + 14 more

Treatment

8 FDA approvals

20 Active Studies for Niacor

What is Niacor

Niacin

The Generic name of this drug

Treatment Summary

Niacin is a type of B vitamin used to treat deficiencies in vitamin B, as well as conditions that affect cholesterol levels, such as hyperlipidemia, dyslipidemia, and hypertriglyceridemia. It can also help to reduce the risk of heart attacks.

O-Cal FA multivitamin

is the brand name

image of different drug pills on a surface

Niacor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

O-Cal FA multivitamin

Niacin

1970

106

Approved as Treatment by the FDA

Niacin, also known as O-Cal FA multivitamin, is approved by the FDA for 8 uses which include High Cardiovascular Risk and Hyperlipidemia .

High Cardiovascular Risk

Used in combination with other therapies

Hyperlipidemia

Used in combination with Sevelamer to help manage Hyperlipidemias

Hardening of the Arteries

Used in combination with Sevelamer to help manage Atherosclerosis

High Cholesterol

Used in combination with Sevelamer to help manage Hyperlipidemias

Coronary Artery Disease

Used in combination with Sevelamer to help manage history of coronary artery disease

dietary supplementation

Used in combination with Niacin for dietary supplementation

Primary Hypercholesterolemia

Used in combination with other therapies

Dietary Modifications

Used in combination with other therapies

Effectiveness

How Niacor Affects Patients

Niacin is a B vitamin commonly used to treat vitamin deficiencies and various forms of high cholesterol. It works by reducing the amount of very low and low-density lipoprotein while increasing levels of high-density lipoprotein, reducing the risk of a heart attack. Niacin’s safe dosage range is 500-2000mg per day, but people with diabetes, kidney problems, underactive thyroid, or who are elderly and taking niacin with certain statin drugs may be at risk of developing muscle pain or damage.

How Niacor works in the body

Niacin has many roles in the body, some of which are still not fully understood. Niacin helps control lipids by reducing the production of triglycerides in the liver and by breaking down triglycerides in fatty tissue. It also prevents the breakdown of HDL, a type of good cholesterol. All of these actions together help to reduce bad cholesterol levels and improve overall heart health.

When to interrupt dosage

The recommended amount of Niacor is contingent upon the determined condition, including inadequate response to diet, Dietary Modifications and Pellagra. The quantity likewise shifts with the technique of delivery (e.g. Oral or Tablet - Oral) featured in the table beneath.

Condition

Dosage

Administration

Coronary Artery Disease

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Risk of pancreatitis

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Combined Modality Therapy

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Dietary Modifications

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

inadequate response to diet

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Hypertriglyceridemia

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

High Cholesterol

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Hardening of the Arteries

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

dietary supplementation

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Primary Hypercholesterolemia

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

cholesterol

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Myocardial Infarction

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Hyperlipidemias

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Triglycerides

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Dyslipidemias

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Pellagra

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

High Cardiovascular Risk

, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL

, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Capsule - Oral, Capsule, Tablet - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release - Oral, Capsule, extended release, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Topical, Shampoo, Shampoo - Topical, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit

Warnings

Niacor Contraindications

Condition

Risk Level

Notes

Hypervitaminosis

Do Not Combine

Liver Dysfunction

Do Not Combine

Transaminases

Do Not Combine

Hemorrhage

Do Not Combine

Liver Diseases

Do Not Combine

Peptic Ulcer

Do Not Combine

Transaminases

Do Not Combine

There are 20 known major drug interactions with Niacor.

Common Niacor Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Niacin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Niacin.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Niacin.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Niacin.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Niacin.

Niacor Toxicity & Overdose Risk

Overdosing on niacin can cause low blood pressure that lasts for a long time. Treatment may involve receiving fluids intravenously. The lowest toxic dose in mice is 3720mg/kg, in rabbits is 4550mg/kg, and in rats is 7000mg/kg. Contact with the skin can also be toxic, with the lowest dose in rats being greater than 2000mg/kg.

image of a doctor in a lab doing drug, clinical research

Niacor Novel Uses: Which Conditions Have a Clinical Trial Featuring Niacor?

44 active clinical trials are presently investigating the potential of Niacor to address inadequate response to dietary measures, cholesterol management and Type II Hyperlipidaemia.

Condition

Clinical Trials

Trial Phases

Coronary Artery Disease

0 Actively Recruiting

dietary supplementation

0 Actively Recruiting

High Cholesterol

19 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Early Phase 1

Dyslipidemias

1 Actively Recruiting

Phase 2

Pellagra

0 Actively Recruiting

cholesterol

4 Actively Recruiting

Phase 3, Not Applicable

Hyperlipidemias

0 Actively Recruiting

Risk of pancreatitis

0 Actively Recruiting

Hardening of the Arteries

17 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3

Primary Hypercholesterolemia

8 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Combined Modality Therapy

0 Actively Recruiting

High Cardiovascular Risk

1 Actively Recruiting

Phase 3

Dietary Modifications

3 Actively Recruiting

Early Phase 1, Not Applicable, Phase 2

Triglycerides

0 Actively Recruiting

Hypertriglyceridemia

6 Actively Recruiting

Phase 3, Phase 2

Myocardial Infarction

0 Actively Recruiting

inadequate response to diet

0 Actively Recruiting

Niacor Reviews: What are patients saying about Niacor?

1

Patient Review

9/27/2008

Niacor for Increased Triglycerides and Cholesterol

I had a really severe reaction to this drug. It felt like my whole body was on fire, and it lasted for about two hours after I took the medication.

Patient Q&A Section about niacor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Niacor the same as niacin?

"There are two brands of prescription niacin - Niacor and Niaspan - as well as a generic form which is usually cheaper."

Answered by AI

What is Niacor prescribed for?

"Niacor is a medication used to lower blood levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides, and increase levels of "good" cholesterol (high-density lipoprotein, or HDL)."

Answered by AI

Who makes Niacor?

"You should discuss the full Prescribing Information for NIACOR with your healthcare provider, which is available on Avondalepharm.com. You can also report any negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch, or by calling 1-800-FDA-1088."

Answered by AI

Is niacin and Niaspan the same thing?

"Niaspan is a medication that contains niacin, a B vitamin (vitamin B3). Niacin is a natural occurring compound found in plants and animals. It's also present in many multiple vitamin supplements. Niaspan is used to lower cholesterol and triglycerides (types of fat) in the blood."

Answered by AI

Clinical Trials for Niacor

Image of University of Alberta in Edmonton, Canada.

Pharmacist-led Care for Diabetes

18+
All Sexes
Edmonton, Canada

As of 2024, nine percent of Albertans are living with Type 2 diabetes, which increases their risk for cardiovascular disease, stroke, blindness, and kidney failure. Unfortunately, less than half of patients have controlled Type 2 diabetes. We are well aware of the factors which lead to worsening diabetes, but need to give people more support to help them manage their diabetes. Pharmacists are respected health care professionals who are often easier to see that doctors and can help people with diabetes to stay as healthy as possible. This research project aims to see whether a pharmacist service can help improve diabetes management in people with type 2 diabetes compared to usual care from their family physician or nurse practitionner. The potential impact of this project is to empower people with type 2 diabetes to understand their condition, it's management, and to achieve target blood sugar levels, which will ultimately reduce the risk of diabetes-related complications.

Recruiting
Has No Placebo

University of Alberta

Ross Tsuyuki, BScPharm, PharmD, MSc

Have you considered Niacor clinical trials?

We made a collection of clinical trials featuring Niacor, we think they might fit your search criteria.
Go to Trials
Image of Lipid Clinic at Brown University Health in Providence, United States.

2-HOBA Supplementation for High Cholesterol

18 - 69
All Sexes
Providence, RI

The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels. The main questions it aims to answer are: Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood? Participants will: Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers

Waitlist Available
Has No Placebo

Lipid Clinic at Brown University Health

Wenliang Song, MD

Have you considered Niacor clinical trials?

We made a collection of clinical trials featuring Niacor, we think they might fit your search criteria.
Go to Trials
Image of Sidney & Lois Eskenazi Hospital in Indianapolis, United States.

Composite Intervention for Metabolic Syndrome

18+
All Sexes
Indianapolis, IN

The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility. Participants (n=20) will be randomized to intervention or control (usual care). The composite intervention will include an educational video outlining the adverse effects of MetS and the benefit of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating practices, periodic text message reminders, and an urgent referral to primary care and our health system's Healthy Me clinic for follow-up visit. Investigators hypothesize that this approach will change patient understanding and motivation to increase physical activity and healthy eating habits.

Recruiting
Has No Placebo

Sidney & Lois Eskenazi Hospital

Image of Duke University Medical Center in Durham, United States.

Cardiometabolic Prevention Clinic for Cardiovascular Disease

18+
All Sexes
Durham, NC

This project is studying whether a team-based specialty clinic can help people with type 2 diabetes and heart disease better manage their blood pressure and cholesterol. The clinic includes coordinated care from heart doctors, kidney doctors, diabetes specialists, and liver doctors. The study will compare two groups of patients: one receiving usual care from their primary care provider, and one referred to the Duke Cardiometabolic Prevention Clinic for multidisciplinary care. The main goals are to find out if this clinic improves blood pressure and cholesterol control over 12 months, increases use of recommended heart medications, and reduces hospital visits and other healthcare use. Participants will be randomly assigned to one of the two groups. Those referred to the clinic will: 1) Meet with a cardiologist for an initial evaluation. 2) Be referred to other specialists (such as endocrinology, nephrology, or hepatology) based on their needs. 3) Receive ongoing, coordinated care from a team of specialists working together to improve their heart and metabolic health.

Recruiting
Has No Placebo

Duke University Medical Center

Neha J Pagidipati, MD, MPH

Image of University of Alabama at Birmingham in Birmingham, United States.

Inspire HER for Cardiovascular Disease

30 - 79
Female
Birmingham, AL

Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.

Recruiting
Has No Placebo

University of Alabama at Birmingham

Timiya S Nolan, PhD

Image of Rush University Medical Center in Chicago, United States.

Health Coaching for Heart Disease

40 - 75
All Sexes
Chicago, IL

The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are: * Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke? * Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes? * Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare? Researchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors. Participants will: * Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6. * Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare * Keep a log of their blood pressure

Waitlist Available
Has No Placebo

Rush University Medical Center

Daniel Luger, MD

Have you considered Niacor clinical trials?

We made a collection of clinical trials featuring Niacor, we think they might fit your search criteria.
Go to Trials